Actively Recruiting
Injectable Platelet-Rich Fibrin Versus Intradermal Tranexamic Acid for Melasma
Led by Kasr El Aini Hospital · Updated on 2026-04-22
21
Participants Needed
1
Research Sites
34 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Melasma is a chronic acquired hyperpigmentation disorder that commonly affects the face and has a significant impact on quality of life. Available treatments may improve pigmentation, but relapse is common and response can be variable. This randomized split-face interventional study aims to compare the efficacy and safety of injectable platelet-rich fibrin (i-PRF) versus intradermal tranexamic acid (TA) in the treatment of facial melasma. Adult female patients with bilateral symmetrical facial melasma will be enrolled. In each participant, one side of the face will be randomly assigned to receive i-PRF and the contralateral side will receive intradermal TA. Patients will undergo five treatment sessions at 2-week intervals. Clinical response will be assessed using the modified Melasma Area and Severity Index (mMASI), Antera 3D camera measurements, Physician Global Assessment, patient satisfaction, and Melasma Quality of Life (MelasQoL) questionnaire. Safety will be evaluated by recording adverse events such as pain, tenderness, erythema, swelling, infection, ecchymosis, and hematoma. The study is designed to determine whether i-PRF is an effective and safe treatment option for melasma compared with intradermal tranexamic acid.
CONDITIONS
Official Title
Injectable Platelet-Rich Fibrin Versus Intradermal Tranexamic Acid for Melasma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Clinical diagnosis of bilateral symmetrical facial melasma (epidermal or mixed type)
- Female participants aged 18 to 50 years
- Fitzpatrick skin types III to IV
- Mild to moderate facial melasma
- No melasma-specific treatment within the previous 4 weeks
- No facial procedures, including peeling, laser resurfacing, or microneedling, within the previous 3 months
- Willing and able to provide written informed consent and comply with study procedures
You will not qualify if you...
- Pregnancy or lactation
- Bleeding or coagulation disorders
- Use of anticoagulants, nonsteroidal anti-inflammatory drugs (NSAIDs), or hormonal contraception
- Active skin infection or facial inflammation
- History of keloids or Koebner-prone conditions, such as psoriasis or vitiligo
- Uncontrolled systemic disease, such as diabetes mellitus or autoimmune disease
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Kasr El Aini Hospital
Cairo, Cairo Governorate, Egypt, 11555
Actively Recruiting
Research Team
H
Heba Ahmed
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here